Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2006
Intestinal disease in Hermansky-Pudlak syndrome: occurrence of colitis and relation to genotypeNadeem Hussain, Martha Quezado, Marjan Huizing, et al.
Cancer Investigation|March 23, 2005
Pathology of the future: molecular profiling for targeted therapyVirginia Espina, David Geho, Arpita I Mehta, et al.
Annual Review of Medicine|January 30, 2004
Serum proteomics in cancer diagnosis and managementKevin P Rosenblatt, Peter Bryant-Greenwood, J Keith Killian, et al.
Cancer Cell|May 3, 2003
Protein microarrays: meeting analytical challenges for clinical applicationsLance A Liotta, Virginia Espina, Arpita I Mehta, et al.
Bioconjugate Chemistry|May 19, 2005
Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarraysDavid Geho, Nicholas Lahar, Prem Gurnani, et al.
Bioconjugate Chemistry|May 18, 2006
Fractionation of serum components using nanoporous substratesDavid Geho, Mark Ming-Cheng Cheng, Keith Killian, et al.
The Lancet. Oncology|October 23, 2012
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyIsabelle Ray-Coquard, Jean-Yves Blay, Antoine Italiano, et al.
Experimental Hematology|May 27, 2006
Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysisRamaprasad Srinivasan, Jasmine Daniels, Vincent Fusaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2013
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune responseXuefeng Yin, Leopoldo Luistro, Hua Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2014
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancersUlrik N Lassen, Didier Meulendijks, Lilian L Siu, et al.
Pageof 2